Charles river laboratories announces strategic lentiviral vector manufacturing collaboration with gates institute at university of colorado anschutz medical campus

Rockville, md.--(business wire)--charles river laboratories international, inc. (nyse: crl) and the gates institute at the university of colorado anschutz medical campus today announced a lentiviral vector contract development and manufacturing organization (cdmo) agreement. gates institute will leverage charles river's premier cell and gene therapy cdmo expertise to develop good manufacturing practice (gmp)-grade lentiviral vectors (lvvs) for use in novel chimeric antigen receptor (car) t-cell.
CRL Ratings Summary
CRL Quant Ranking